DS Waters extends partnership with Susan G. Komen for the Cure

November 05, 2015

"The results of this study mean that not only do physicians have an additional, powerful tool to help treat breast cancer but that PEM is a legitimate and better alternative for the 16% of women who cannot tolerate MR due to claustrophobia, metallic implants, body habitus, or gadolinium reaction," said Wendie Berg, M.D., Ph.D. and Principal Investigator for the trial.  Berg recently published an article in the January 2010 issue in the journal Radiology examining the reasons why high-risk women who were recommended for a MR breast screening test refused to take the exam.

PEM scanners are high-resolution breast PET systems that can show the location as well as the metabolic phase of a lesion.  This information is critical in determining whether a lesion is malignant and influences the course of treatment.  Other imaging systems, such as mammography and ultrasound, show only the location, not the metabolic phase. PEM scanners, which are about the size of an ultrasound system, are manufactured by Naviscan, Inc. and have been commercially available since 2007.

The NIH-sponsored multi-site study (NIH Grant 5R44CA103102) examined women with newly-diagnosed breast cancer. Patients were accrued from six leading clinical centers across the country: ARS Johns Hopkins Green Spring, Boca Raton Community Hospital, Scripps Clinic-Scripps Green Hospital, University of North Carolina, University of Southern California Norris Cancer Center, and Anne Arundel Medical Center.

SOURCE Naviscan, Inc.